Creative Biolabs: With a Good Vision, We Greet on a Prosperous New Year

Creative Biolabs, a CRO dedicated to the research on SARS-CoV-2 and relevant mutants in terms of virology and drug and vaccine discovery, congratulates on a happy new year and hopes that prosperous results of SARS-CoV-2 therapeutics will yield with joint efforts.

New York, United States – January 9, 2023 /MarketersMEDIA/ —

Good news coming alongside the Christmas and New Year holidays was that a new study related to the control of SARS-CoV-2 infection was published in the journal Nature Communications, presenting a promising route that may help curb the spread of SARS-CoV-2 and emerging mutants. 

The entire globe is working arduously to defend against SARS-CoV-2, which first staged its appearance in the winter of 2019. Thankfully, positive results were yielded in time, with several potent preventive vaccines developed and approved for use. Yet there’s still a long way to go, as more precise approaches to curbing the infection and efficacious therapeutic options are urgently needed.

Creative Biolabs is among the CROs supporting SARS-CoV-2 research and drug discovery, offering comprehensive solutions covering not only research-use antibodies (e.g., SARS-CoV-2 therapeutic human monoclonal antibody), IVD immunoassay development, as well as drug discovery.

“The most valid method to control the spread of COVID-19 is still vaccines, among which DNA vaccine is gaining a place in that it is outstanding in performance, flexible for monitoring, and convenient to produce,” according to a specialist with profound experience dealing with coronavirus-related projects, “and our SARS-CoV-2 DNA vaccine service can be a wise option for involving researchers.”

Quite a ratio of Creative Biolabs’ efforts is related to antiviral drug development, covering all the mainstream therapeutic routes on the research market, such as complement therapeutics, protease inhibitors, and neutralizing antibodies.

Efficacy and safety profiles are also core factors to be validated before moving a candidate onto the next stage, maybe the clinical. “We’ve also set up exclusive platforms for SARS-CoV-2 drug validation,” added the specialist, “aiming to provide the most comprehensive and exhaustive analytical report.” The system covers:

• Reverse genetics systems
• Cell lines: ACE2-overexpressing stable cell lines & spike-expressing stable cell lines
• Spike-pseudovirus based neutralization assay
• Protease inhibitor assay

“We’re expanding our capabilities, as viruses are constantly evolving and new ones are presenting faster than ever before. We’re on the verge of success, and hopefully, in 2023, we can put the matter to rest jointly.”

Official web: https://sars-cov-2.creative-biolabs.com/

Overview

Creative Biolabs contributes to SARS-CoV-2 drug discovery with its peer-acclaimed products and skillful solutions and has earned a good reputation across the industry owing to its professionalism and dedication. In January, a group of scientists will kick off a year of networking with industry vendor events at Rutgers University and PepTalk – The Protein Science and Production Week.

Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://sars-cov-2.creative-biolabs.com/

Release ID: 89087848

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.